Test Price
800 AED✅ Home Collection Available
Menopausal Screening Panel in UAE | 800 AED | Comprehensive Hormonal Assessment
Executive Summary & Core Metrics
- ✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via CLIA/EIA validated against LC-MS/MS reference methodology, processed in our ISO 9001:2015 Certified Facility (Cert: INT/EGQ/2509DA/3139).
- ✓ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection — available 8 AM to 11 PM daily across all Emirates.
- ✓ Clinical Guidance: Telephonic Post-Test Clinical Guidance by a DHA-licensed physician to support result interpretation and next-step planning.
- ✓ Insurance Support: Direct Billing Verification via WhatsApp at +971 54 548 8731 — instant confirmation for 40+ UAE insurer networks.
Test Overview & Methodology
The Menopausal Screening Panel is a comprehensive hormonal evaluation designed to assess ovarian function and menopausal status through quantitative measurement of key reproductive hormones — including Follicle-Stimulating Hormone (FSH), Luteinizing Hormone (LH), Estradiol (E2), and Progesterone — using Chemiluminescent Immunoassay (CLIA) and Enzyme Immunoassay (EIA) technologies. This panel serves as an essential diagnostic tool for perimenopausal transition assessment, premature ovarian insufficiency screening, and treatment monitoring for women experiencing vasomotor symptoms, menstrual irregularities, or fertility concerns in the UAE.
| Feature | Our Test — Menopausal Screening Panel | Closest Alternative — Standard Hormone Panel |
|---|---|---|
| Methodology | CLIA + EIA (dual-platform, cross-validated vs. LC-MS/MS reference) | Single-platform immunoassay only; limited cross-validation |
| Analytical Sensitivity | ≥99.9% — ISO 9001:2015 validated | Typically 95–97%; variable QC protocols |
| Turnaround Time | Same Day (sample by 9 AM) | 2–5 working days |
| Home Collection | Included — ISO Cold-Chain, 8 AM–11 PM | Often unavailable or surcharged |
| Post-Test Consultation | Included — DHA-licensed physician tele-guidance | Rarely included; requires separate GP visit |
| Price | 800 AED (All-Inclusive) | 600–1,200 AED (variable; excludes consult) |
Physician Insight & Safety Protocols
Dr. Ajay Singh, MBBS — DHA License: 36234132
General Practitioner | Primary Care & Wellness Medicine
"The Menopausal Screening Panel provides valuable objective data that helps women and their healthcare providers navigate the perimenopausal transition with clarity. As a general practitioner, I view this panel as a first-line screening tool that quantifies hormonal shifts, which then informs timely referrals to gynecologists or endocrinologists when deeper intervention is needed."
"I emphasize to every patient that a single lab report does not define your health journey. These numbers must be woven together with your personal symptoms, family history, and lifestyle factors. Our telephonic follow-up is designed to help you contextualize results and determine the most appropriate next steps — whether that is watchful waiting, lifestyle adjustments, or specialist consultation."
"With over a decade of clinical practice in the UAE, I have seen how early and accurate hormonal assessment empowers women to make informed decisions about bone health, cardiovascular risk, and quality of life during the menopausal transition."
Clinical Medication Advisory
Important Medication Advisory
Do not discontinue any prescribed medication — including Hormone Replacement Therapy (HRT), oral contraceptives, or any endocrine-modulating drug — without consulting your treating physician prior to or following this test. Abrupt cessation of hormonal therapy may precipitate significant adverse physiological effects and confound diagnostic interpretation.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria (Do NOT proceed without physician clearance):
- Confirmed or suspected pregnancy — must be ruled out via serum β-hCG prior to menopausal panel interpretation
- Active use of combined hormonal contraceptives without documented physician awareness
- Current Hormone Replacement Therapy (HRT) without a minimum 6-week washout period (unless monitoring on-therapy levels per specialist directive)
- Recent (within 8 weeks) unilateral or bilateral oophorectomy
- Active chemotherapy or pelvic radiation therapy — gonadal suppression confounds results
ER Red Flags — Seek Immediate Medical Attention:
- Heavy, uncontrolled vaginal bleeding with clots larger than 2 cm or soaking through pads hourly
- Acute, severe pelvic or lower abdominal pain of sudden onset
- Signs of rapid-onset hyperandrogenism: sudden voice deepening, hirsutism, or clitoromegaly
- Postmenopausal bleeding (any vaginal bleeding occurring ≥12 months after last menstrual period)
- Syncope, dizziness, or hemodynamic instability with pelvic symptoms
Patient FAQ & Clinical Guidance
1. What does the Menopausal Screening Panel measure, and how is it interpreted?
The Menopausal Screening Panel quantitatively measures serum FSH, LH, Estradiol (E2), and Progesterone levels to assess ovarian reserve and function. These results provide objective biochemical data that must be interpreted alongside clinical symptoms, age, and menstrual history by a DHA-licensed physician. Elevated FSH levels (typically ≥25–30 IU/L) in conjunction with low Estradiol suggest diminished ovarian function consistent with perimenopause or menopause. A single measurement is not diagnostic; serial trends and clinical correlation are essential. Our telephonic post-test guidance ensures you receive context-specific interpretation aligned with current DHA clinical pathways.
2. Is fasting required before the Menopausal Screening Panel, and can medications affect results?
No fasting is required for this blood test. However, certain medications — including hormonal contraceptives, HRT, biotin supplements exceeding 5 mg daily, and some herbal preparations — can significantly alter hormone measurements. You must disclose all current medications, supplements, and hormonal therapies to your ordering physician prior to sample collection. We recommend scheduling your draw in the morning (8–11 AM) when FSH and Estradiol levels are most stable for clinical interpretation. If you are on HRT, your physician may advise a monitored washout period or interpret results in the context of ongoing therapy. Never self-discontinue prescribed hormones.
3. How accurate is this panel for diagnosing menopause, and when should I repeat it?
With 99.9% analytical sensitivity via dual-platform CLIA/EIA methodology cross-validated against LC-MS/MS reference standards, this panel provides highly reliable hormonal data. Clinical diagnosis of menopause requires 12 consecutive months of amenorrhea and may necessitate repeat testing at 4–6 week intervals for perimenopausal women with irregular cycles. For women under 40 with suspected premature ovarian insufficiency (POI), at least two FSH measurements in the menopausal range taken 4–6 weeks apart are recommended per international guidelines. Our same-day reporting enables rapid serial monitoring without prolonged diagnostic uncertainty.
UAE Regulatory & Data Privacy Adherence
Legal Framework
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) — full compliance for patient data handling and storage
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields — governs electronic health records and telemedicine
- Federal Decree-Law No. 4 of 2016 on Medical Liability — governs clinical testing safety and patient consent protocols
Quality Certifications
- ISO 9001:2015 — Cert: INT/EGQ/2509DA/3139
- DHA Facility License: 1143
- CLIA/EIA platforms cross-calibrated to LC-MS/MS reference standards quarterly
- Methodology validated per UAE health data harmonization protocols
Clinical Oversight
- Dr. Ajay Singh — General Practitioner (DHA 36234132)
- Clinical Pathologist — Laboratory Quality Assurance
- Corporate Oversight: DNA Labs UAE
Clinical & Logistical Metadata
| Test Name | Menopausal Screening Panel |
| Price (AED) | 800 AED (All-Inclusive) |
| Turnaround Time | Same Day (sample by 9 AM) |
| Sample Type / Matrix | Serum (SST — Serum Separator Tube, 5 mL) |
| Methodology Used | CLIA (Chemiluminescent Immunoassay) + EIA/ELISA (Enzyme Immunoassay) |
| ICD-10-CM Code | Z78.0 (Menopausal state) |
| LOINC Code | 75724-5 (Menopause panel – Serum) |
| DHA Facility License & Laboratory Address | License #1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE — DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians